Why Do Phase III Clinical Trials in Oncology Fail so Often?

被引：40
作者：
Amiri-Kordestani, Laleh [1 ]
Fojo, Tito [1 ]
机构：
[1] NCI, Med Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2012年 / 104卷 / 08期
关键词：
DRUG DEVELOPMENT; TARGETED AGENTS; STABLE DISEASE; END-POINT; CHEMOTHERAPY; SURVIVAL; CANCER; BENEFIT; DESIGNS;
D O I：
10.1093/jnci/djs180
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：568 / 569
页数：2
相关论文
共 50 条
[31]   Lung Cancer Clinical Trials with a Seamless Phase II/III Design: Systematic Review [J].
Palermos, Dionysios ;
Sergentanis, Theodoros N. ;
Gavriatopoulou, Maria ;
Malandrakis, Panagiotis ;
Psaltopoulou, Theodora ;
Terpos, Evangelos ;
Ntanasis-Stathopoulos, Ioannis .
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (23)
[32]   Performance Status Restriction in Phase III Cancer Clinical Trials [J].
Jaoude, Joseph Abi ;
Kouzy, Ramez ;
Mainwaring, Walker ;
Lin, Timothy A. ;
Miller, Austin B. ;
Jethanandani, Amit ;
Espinoza, Andres F. ;
Pasalic, Dario ;
Verma, Vivek ;
VanderWalde, Noam A. ;
Smith, Benjamin D. ;
Smith, Grace L. ;
Fuller, C. David ;
Das, Prajnan ;
Minsky, Bruce D. ;
Roedel, Claus ;
Fokas, Emmanouil ;
Jagsi, Reshma ;
Thomas, Charles R., Jr. ;
Subbiah, Ishwaria M. ;
Taniguchi, Cullen M. ;
Ludmir, Ethan B. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (10) :1322-1326
[33]   An overview of randomized phase III clinical trials of cancer nanomedicines [J].
Melo, Micael N. ;
Amaral, Ricardo G. ;
de Andrade, Lucas R. Melo ;
Severino, Patricia ;
Blanco-Llamero, Cristina ;
Andrade, Luciana N. ;
Souto, Eliana B. .
CANCER PATHOGENESIS AND THERAPY, 2025, 3 (04) :322-336
[34]   Sample size estimation in phase III cancer clinical trials [J].
Curran, D ;
Sylvester, RJ ;
Boes, GH .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1999, 25 (03) :244-250
[35]   Phase III Clinical Trials That Integrate Treatment and Biomarker Evaluation [J].
Freidlin, Boris ;
Sun, Zhuoxin ;
Gray, Robert ;
Korn, Edward L. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (25) :3158-3161
[36]   Why providers participate in clinical trials: Considering the National Cancer Institute's Community Clinical Oncology Program [J].
McAlearney, Ann Scheck ;
Song, Paula H. ;
Reiter, Kristin L. .
CONTEMPORARY CLINICAL TRIALS, 2012, 33 (06) :1143-1149
[37]   Evidence-based medicine in oncology:: Do the results of trials reflect clinical reality [J].
Hoelzel, D. ;
Schubert-Fritschle, G. .
ZENTRALBLATT FUR CHIRURGIE, 2008, 133 (01) :15-19
[38]   Phase 0 clinical trials in oncology: a paradigm shift for early drug development? [J].
Takimoto, Chris H. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (04) :703-709
[39]   Early phase oncology clinical trials in Malaysia: current status and future perspectives [J].
Voon, Pei-Jye ;
Lai, Wei-Hong ;
Bustaman, Ros Suzanna ;
Siu, Lillian L. ;
Razak, Albiruni R. Abdul ;
Yusof, Akhmal ;
Abdullah, Noor Hisham .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 (03) :296-304
[40]   Patients' selection and trial matching in early-phase oncology clinical trials [J].
Corbaux, P. ;
Bayle, A. ;
Besle, S. ;
Vinceneux, A. ;
Vanacker, H. ;
Ouali, K. ;
Hanvic, B. ;
Baldini, C. ;
Cassier, P. A. ;
Terret, C. ;
Verlingue, L. .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 196
12345